How do we tackle immune-related toxicities when using bispecific antibodies?
22 Sep 2025
Bi/Multispecifics
- How is cytokine release syndrome (CRS) managed, and what is the role of Tocilizumab in its treatment?
- How is Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) managed?
- How are cytopenias, infections, and tumor lysis syndrome (TLS) monitored and managed in patients?
- What is the safest venue for the administration of this therapy?
